Keywords: Pfizer, Champix, Smoking cessation, Research

More smokers quit habit with Pfizer’s Champix than with placebo

Article | 6 November 2009

• Print This

Findings from a Pfizer-sponsored study, presented as late-breaker at American College of Chest Physicians annual meeting in San Diego, showed that 42.3% of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took the firm’s Champix (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8% of those given placebo (p<0.0001).>

“Quitting smoking is of paramount importance for all smokers, particularly those with a smoking-related illness, such as COPD,” said Donald Tashkin, study investigator, emeritus professor of medicine at University of California, Los Angeles. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.